US Bancorp’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,380
| Closed | -$55.5K | – | 4166 |
|
|
2026
Q1 | $55.5K | Sell |
1,380
-1,662
| -55% | -$35.8K | ﹤0.01% | 2663 |
|
|
2025
Q4 | $76.4K | Buy |
3,042
+376
| +14% | +$8.82K | ﹤0.01% | 2502 |
|
|
2025
Q3 | $60.3K | Sell |
2,666
-390
| -13% | -$9.1K | ﹤0.01% | 2589 |
|
|
2025
Q2 | $52.9K | Buy |
3,056
+711
| +30% | +$13.2K | ﹤0.01% | 2757 |
|
|
2025
Q1 | $51.3K | Sell |
2,345
-878
| -27% | -$24.3K | ﹤0.01% | 2731 |
|
|
2024
Q4 | $103K | Buy |
3,223
+1,327
| +70% | +$39.9K | ﹤0.01% | 2385 |
|
|
2024
Q3 | $54.7K | Sell |
1,896
-983
| -34% | -$36.4K | ﹤0.01% | 2682 |
|
|
2024
Q2 | $110K | Sell |
2,879
-687
| -19% | -$31.1K | ﹤0.01% | 2288 |
|
|
2024
Q1 | $210K | Sell |
3,566
-274
| -7% | -$17.5K | ﹤0.01% | 1984 |
|
|
2023
Q4 | $230K | Sell |
3,840
-58
| -1% | -$2.94K | ﹤0.01% | 1934 |
|
|
2023
Q3 | $148K | Buy |
3,898
+2,564
| +192% | +$113K | ﹤0.01% | 1963 |
|
|
2023
Q2 | $122K | Buy |
1,334
+23
| +2% | +$1.98K | ﹤0.01% | 2102 |
|
|
2023
Q1 | $86.5K | Buy |
1,311
+597
| +84% | +$34.4K | ﹤0.01% | 2263 |
|
|
2022
Q4 | $36.9K | Sell |
714
-3,553
| -83% | -$188K | ﹤0.01% | 2691 |
|
|
2022
Q3 | $291K | Buy |
4,267
+3,902
| +1,069% | +$231K | ﹤0.01% | 1654 |
|
|
2022
Q2 | $17K | Sell |
365
-745
| -67% | -$34K | ﹤0.01% | 3130 |
|
|
2022
Q1 | $56K | Buy |
1,110
+884
| +391% | +$39K | ﹤0.01% | 2558 |
|
|
2021
Q4 | $11K | Sell |
226
-117
| -34% | -$4.61K | ﹤0.01% | 3379 |
|
|
2021
Q3 | $12K | Buy |
343
+203
| +145% | +$11.4K | ﹤0.01% | 3347 |
|
|
2021
Q2 | $9K | Buy |
140
+33
| +31% | +$1.7K | ﹤0.01% | 3420 |
|
|
2021
Q1 | $4K | Hold |
107
| – | – | ﹤0.01% | 3532 |
|
|
2020
Q4 | $6K | Buy |
107
+77
| +257% | +$3.26K | ﹤0.01% | 3330 |
|
|
2020
Q3 | $1K | Sell |
30
-43
| -59% | -$1.28K | ﹤0.01% | 3558 |
|
|
2020
Q2 | $2K | Buy |
+73
| New | +$2.34K | ﹤0.01% | 3477 |
|
Other funds holding APLS
US Bancorp's APLS Position: Q2 2026 in Review
US Bancorp sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,380 shares — an estimated $55.5K sold.
US Bancorp first reported a position in APLS in Q2 2020 and held it in 24 quarters. The position peaked at $291K in Q3 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- US Bancorp reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- US Bancorp sold 1,380 Apellis Pharmaceuticals shares in Q2 2026, an estimated $55.5K.
- US Bancorp first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 24 quarters.
- US Bancorp's Apellis Pharmaceuticals position peaked at $291K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.